SeraCare posted a net income of $1.31m for the third quarter 2010, or $0.07 per diluted share, compared to $697,019, or $0.04 per diluted share, for the comparable period in 2009.
Operating income was $1.39m, compared to $771,562 for the comparable period in 2009.
Net income was $4.7m, or $0.24 per diluted share, compared to $16.82m, or $0.91 loss per diluted share, for the year ago period.
SeraCare serves global life sciences industry by providing products and services to facilitate the production, discovery and development of human therapeutics and diagnostics.
